The effectiveness of the vaccine from the coronavirus company Astrazeneca was 3 percent lower than previously declared. This company announced this after testing the drug in the United States, the application is posted on its website.
Studies have shown that from the flow of COVID-19 with Cymptoms, it saves 76 percent of cases, and not in 79, as it was thought before. At the same time, effectiveness in preventing severe cases of disease requiring hospitalization is still 100 percent, and efficiency in the use of patients aged 65 years and older – 85 percent.
Earlier on March 25, it became known that the Ministry of Health of Canada added a warning about the possibility of thrombosis to the instructions of the drug Astrazeneca, although no such case was recorded in the country.
Currently, a number of European countries have suspended or banned vaccination with Astrazeneca due to the discovery of thrombosis in the intimidated patients. Meanwhile, the creators of the vaccine insist on its safety. The company stated that a detailed study of the health of more than 17 million people after vaccination showed the absence of data on the increased risk of the emergence of a pulmonary artery embolusion, deep vein thrombosis or thrombocytopenia.
Representatives of the European Medicine Agency (EMA), in turn, reported 22 cases of thrombosis by three million villages in the EU.